Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-01-03 Erythropoietin
| Epoetin alfa Eprex® |
|
Formulary
|
| Injection prefilled syringe 10,000units, 40,000units Consultant initiation only |
|
Links
NICE NG203: Chronic kidney disease: assessment and management- NICE TA1000: Iptacopan for treating paroxysmal nocturnal haemoglobinuria
- NICE TA323: Epoetin and darbepoetin for anaemia in people having chemotherapy
- NICE TA636: Eculizumab for treating refractory myasthenia gravis (terminated appraisal)
- NICE TA647: Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
- NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
- NICE TA698:Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
- NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
- NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
- NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
- NICE TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease